Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 9/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18166117 | 0.96 | MBOAT4 (0.59) | MBOAT4KDM4EPKMFAAHGPR119 | |
| SCHEMBL28406437 | 0.96 | MBOAT4 (0.59) | MBOAT4KDM4EPKMFAAHGPR119 | |
| SCHEMBL28406440 | 0.96 | MBOAT4 (0.59) | MBOAT4KDM4EPKMFAAHGPR119 | |
| SCHEMBL20009391 | 0.89 | MBOAT4 (0.50) | MBOAT4KDM4EPKMFAAHGPR119 | |
| SCHEMBL16699845 | 0.88 | MBOAT4 (0.49) | MBOAT4KDM4EPKMFAAHGPR119 | |
| SCHEMBL16699213 | 0.85 | MBOAT4 (0.69) | MBOAT4FAAH | |
| SCHEMBL18166101 | 0.85 | MBOAT4 (0.61) | MBOAT4KDM4EPKM | |
| SCHEMBL18154031 | 0.85 | MBOAT4 (0.53) | MBOAT4KDM4EPKMFAAHGPR119 | |
| SCHEMBL19984468 | 0.84 | MBOAT4 (0.86) | MBOAT4 | |
| SCHEMBL16718675 | 0.84 | MBOAT4 (0.86) | MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107454898-B | Ghrelin O-acyltransferase inhibitors | 伊莱利利公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| EP-3283474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | Eli Lilly and Company (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3068775-B1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | LILLY CO ELI (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3068775-B1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | LILLY CO ELI (US) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
| EP-3068775-A1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | Eli Lilly and Company (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073281-A1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073281-A1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-9035051-B1 | Ghrelin O-acyl transferase inhibitor | ELI LILLY AND COMPANY (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035051-B1 | Ghrelin O-acyl transferase inhibitor | ELI LILLY AND COMPANY (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035051-B1 | Ghrelin O-acyl transferase inhibitor | ELI LILLY AND COMPANY (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885KDM4E 961/4885PKM 4714/4885 |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885KDM4E 961/4885PKM 4714/4885 |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | MBOAT4, DGAT1, MOGAT2 | MBOAT4 1/4885KDM4E 913/4885PKM 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.